Alizé Pharma 3
Alizé Pharma 3 to present data from its AZP-3404 program in syndromes of severe insulin resistance at ENDO 2019
Millendo Therapeutics
Millendo Therapeutics Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome.
JHAM3: Jumelage Handicap Aide Madagascar
The 3rd phase, JHAM3, launched in 2018 with a collection of items such as adaptive equipment, games, educational toys and books, stationery, school supplies, clothing and household linen.
The 33 m3 container left France on the 28th December en route for Toamasina in Madagascar, and we distributed the equipment to ten Malagasy organisations during our mission between the 3rd and 17th March.
Millendo Therapeutics
Millendo Therapeutics Announces ENDO 2019 Presentations on Livoletide for Prader-Willi Syndrome and Nevanimibe for Classic Congenital Adrenal Hyperplasia.
One new project supported by our Foundation
The 8th of february 2019, the board of directors of the Fondation Dominique & Tom Alberici decided to support the MIETE by helping to organise its Fest’Dif festival in Villeurbanne (Rhône) on the 5th and 6th July 2019, which aims to promote difference and diversity.
Alizé Pharma 3
Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company focused on rare endocrine and metabolic diseases
JHAM2: Jumelage Handicap Aide Madagascar
The JHAM 2 project aims to implement a collective educational programme in 2017 following an observation phase.
A container has been sent in june 2017